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Ebolavirus outbreaks
PLoS Pathog. 2015 Nov; 11(11)
• Ebola virus disease (EVD) is a severe, often fatal illness in humans (~50% 
fatality)
• The most recent (2014) outbreak was reported in Guinea (and 5 additional 
West African countries). 
• Ebola virus (EBOV) is considered a biological warfare threat agent.  
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Structure of the Ebola virus glycoprotein
Nature. 2008 Jul 10;454(7201):177-82
• EBOV is an enveloped, negative-sense, single-stranded RNA virus.  The 
genome of EBOV encodes seven proteins. 
• Several vaccines and antibodies based on EBOV GP are under 
development, including viral vaccines and subunit GP vaccines, virus-like 
particles (VLP) and multiple recombinant monoclonal antibodies. 
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• Nicotiana benthamiana plants are vacuum infiltrated with agrobacteria 
carrying GOI(s) in a non-viral vector, under control of strong plant-based 
promoters.  
• Plants are allowed to grow for 2-8 days, then are harvested and accumulated 
protein is extracted.  
Agrobacteria
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Plant-expression system - vacuum infiltration
Not Infiltrated Infiltrated with GFP
• Gene expression is observed mainly in leaves, as demonstrated in plants 
infiltrated with green fluorescent protein (above). 
• Plant-based systems enable proper folding and disulfide bond formation
• Multiple proteins or subunits can be expressed simultaneously (such as 
heavy and light chain of IgGs). 
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Plant-based expression of EBOV 
virus-like particle vaccines
Disclaimer :  
This project has been funded in part with federal funds from JPM-
Medical Countermeasure Systems. 
Opinions, interpretations, conclusions, and recommendations are 
those of the authors and are not necessarily endorsed by the U.S. 
Army under subcontract to Battelle.
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Design and production of non-enveloped VLPs
AlMV CPZGP (∆TM)N C
Dialysis/Concentration
TEM
• ZGP(∆TM)-CP fusion protein is expressed in plants, extracted and affinity purified.










© Fraunhofer USA Center for Molecular Biotechnology
Extraction/
clarification







High speed centrifugation 
(100,000 xg) 
• The full-length ZGP is expressed in plants, eVLPs are extracted and fractionated using 
sucrose gradient, then concentrated by ultracentrifugation.  
Design and production of enveloped VLPs
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Mouse challenge - study outline
• Groups of 10 mice were vaccinated (i.m.) with :
• FhCMB CP-VLP vaccine (FhCMB adjuvant, saponin-based)
• FhCMB eVLP vaccine (FhCMB adjuvant, saponin-based)
• FhCMB adjuvant only
• Two immunizations, 4 weeks apart
• Mice were challenged (i.p) with 1,000 PFU/mL in 0.25 mL of mouse-adapted EBOV 
(in ABSL-4)
Day 0 Day 28 Day 56
Vaccine Vaccine Challenge 
© Fraunhofer USA Center for Molecular Biotechnology
Survival rates for FhCMB eVLP vaccinated groups
• EBOV-infected control animals died within 3-5 days, significant proportion of 
vaccinated animals survived the challenge up to 21 days post infection.  
• The extent of protection was dependent on the dose of vaccine. 
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Survival rates for FhCMB CP-VLP vaccinated groups
• EBOV-infected control animals died within 3-5 days, significant proportion of 
vaccinated animals survived the challenge up to 21 days post infection.  
• At least 70% survival was observed in groups vaccinated with CP-VLP vaccine.
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Disclaimer :  
This project has been funded with federal funds from BARDA. 
Opinions, interpretations, conclusions, and recommendations are 
those of the authors and are not necessarily endorsed by 
BARDA/ASPR/HSS. The goal was to validate Nicotiana
benthamiana expression systems for anti-Ebola mAbs.
Plant-based expression of monoclonal antibodies
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DoD 10-30 grams In vivo
Ebola (Sudan)
Multiple mAbs
DoD 0.1-0.5 grams In vitro
Anthrax DoD Bench scale In vivo
VEEV DoD 12-15 grams In vivo
Clostridium 
difficile
Internal Bench scale In vitro
Influenza Internal Bench scale In vivo
• Recent examples of plant-based biologics are Ebola Zaire and Sudan 
mAbs (under contract from DoD) 
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Sites of interaction between EBOV GP and 
neutralizing antibodies 
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17182
• Neutralizing mAbs (such as c2G4, c4G7) bind at the GP1–GP2 
interface and can prevent structural changes in GP2 required for 
membrane fusion. 
• Non-neutralizing antibodies (such as c13C6, 13F6) bind outside of the 
core GP.
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Schematic representation of plant 
expression vectors
RB Heavy ChainD35S pA LB RB Light ChainD35S pA LB+
• Variable regions of heavy or light chain are cloned into a Nicotiana
benthamiana expression vector containing human antibody 
constant regions
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Condition A Condition B
• Plasmids carrying light and heavy chains are agroinfiltrated into N. 
benthamiana, and plants are harvested at 4, 5, 6, and 7 days post infiltration.  
• The extracts are prepared and clarified, and antibodies are affinity purified on 
Protein A.  
• Growth conditions and harvest time are optimized to maximize yields.  
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Harvest, homogenization, 
clarification





UFDF into final formulation
Filtration 0.22 µm/bottling for 
BDS
Dilution prior to AEX
The downstream process (mAbs)
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Comparable to reference 
standard or described MWt
of bands
Comparable to reference 




UV (A280) 15 - 30 mg/mL 27.3 mg/mL
Purity Bioanalyzer ≥ 90% of main target peak 98.5%
Purity SEC ≤ 10% aggregates
< 10% aggregates 
(no aggregates detected)
Appearance Visual
Clear to slight amber 
solution 




Report value 304 mOsm/kg
pH Potentiometric 5.5 - 6.5 6.2
Bacterial 
Endotoxin
LAL Report value 0.05 EU/mg
Bioburden Aerobic growth ≤ 10 CFU/mL
< 10 CFU/mL 
(no growth observed)
Quality Control Release Data for Antibody c13C6
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Reactivity of plant-based Ebola antibodies with a 
recombinant EBOV GP fragment
mAb
EC50 ng/mL (Ave (STDV))
BDS-001 BDS-002
c13C6_FhCMB 14.5 (1.29) 15.0 (2.45)
c2G4_FhCMB 26.0 (2.16) 27.6 (1.71)
c4G7_FhCMB 20.0 (1.41) 17.5 (1.73)
c13C6_IBT 12.0 (1.13)
ELISA against  rZEBOV GPdTM (IBT Bioservices)
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Column: Zenix-C SEC-300 
Sample diluted to 2 mg/mL with PBS
Mobile Phase: PBS




SEC   c2G4-BDS; CMB-BDS-1410-001
Short term stability of Ebola mAb
• Product is stable up to 6 months when stored at -60⁰C or below and no 
aggregation was observed
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Rapid production timeline example
DNA synthesis and cloning 
Development of upstream process
Development of downstream process
Establishment of assays 
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Guinea pig study outline
• On Day 0, the animals received 1000 pfu of EBOLA Virus Guinea Pig-adapted 
Mayinga by the intraperitoneal (i.p.) route.   
• Antibodies were administered i.p. 72 +/- 2 hours after infection. 
• Animals were monitored and blood samples collected for virology, 
hematology and clinical chemistry.
Day 0 Day 3 Day 21
mAbsChallenge 
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FhCMB mAbs 14 0.0031
Placebo 6.5 N/A
*Gehan-Breslow-Wilconxon test
• Six Hartley Guinea pigs (250 to 350 grams) received 1000 pfu of EBOLA 
Virus Guinea Pig-adapted Mayinga by the i.p. route.
• Antibodies (combined dose of 5 mg/animal) were administered 3 days post 
infection. 
• Treatment with anti-Ebola mAbs extended survival to 14 days, as compared 
to placebo (PBS) group, for which median survival was 6.5 days.  
© Fraunhofer USA Center for Molecular Biotechnology
Summary
• Two recombinant vaccine candidates based on Ebola surface 
GP were expressed in N.benthamiana and purified as 
enveloped and non-enveloped VLPs and their in vivo efficacy 
demonstrated.
• Rapid production of three Ebola monoclonal antibodies in N. 
benthamiana was demonstrated and in vivo protective activity 
was confirmed.  
• Major advantages of plant-based expression systems include:  
• Ability to produce large quantities of target proteins at low cost
• The presence of an eukaryotic post-translational modification 
machinery
• Low risk to introduce human pathogens
• Plant tissues can be inexpensively processed for oral delivery
• The results warrant further development of a novel plant-based 
vaccines and biologics.  
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